Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom英伟达支持的Iambic Therapeutics启动IPO，生物科技公司逆市场低迷而上
Oct 8 (Reuters) - Nvidia-backed Iambic Therapeutics, which uses AI to develop drugs, is aiming to raise up to $159.4 million in its US IPO, as the biotech sector emerges as a bright spot in an otherwise lackluster market.
An Nasdaq logo, in this illustration taken September 28, 2026. REUTERS/Dado Ruvic/Illustration
Oct 8 (Reuters) - Nvidia-backed Iambic Therapeutics, which uses AI to develop drugs, is aiming to raise up to $159.4 million in its USIPO, as the biotech sector emerges as a bright spot in an otherwise lackluster market.
The initial public offering would value the drugmaker at up to $805.8 million — towards the top of its indicated price range — based on the number of outstanding shares listed in its prospectus, a regulatory filing showed on Tuesday.
Thank you for your report!
ASML, Zeiss say next-generation chipmaking technology may be ready in 10 years
Five technology drivers identified as critical to Malaysia's sovereignty, Parliament hears
Industrial investors get clean energy supply through new technology park partnership
纳斯达克标志，图中拍摄于 2026 年 9 月 28 日。REUTERS/Dado Ruvic/Illustration
10 月 8 日（路透社）——英伟达支持的 Iambic Therapeutics 公司利用人工智能开发药物，计划在美国首次公开募股 (IPO) 中筹集至多 1.594 亿美元，生物技术行业在其他方面表现平平的市场中成为亮点。
周二公布的监管文件显示，根据招股说明书中列出的流通股数量，这家制药公司的首次公开募股估值将高达 8.058 亿美元——接近其指示价格区间的上限。
感谢您的报告！
ASML和蔡司表示，下一代芯片制造技术可能在10年内准备就绪。
国会获悉，五项技术驱动因素被认定为对马来西亚主权至关重要。
工业投资者通过与新型科技园区的合作，获得清洁能源供应。